To hear about similar clinical trials, please enter your email below
Trial Title:
Role of Irisin/FNDC5 (rs3480) Single Nucleotide Polymorphism in Breast Cancer
NCT ID:
NCT05876728
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Genetic
Intervention name:
Genotyping
Description:
Genotyping of rs 3480 of irisin gene using the Taqman Allelic Discrimination assay
technique.
Arm group label:
cases group
Arm group label:
control group
Summary:
Breast cancer is the most frequent cancer in women worldwide. Its incidence is increasing
but mortality has decreased in a considerable way due to the combined effect of early
detection and improvement in treatment .
Irisin is encoded by the FNDC5 gene, whose expression is controlled by the peroxi- some
proliferator activated receptor gamma coactivator 1 alpha (PGC-1α). PGC-1α is a
transcriptional co-activator which does not bind directly to DNA. Studies indicated that
the estrogen-related receptor alpha (ERRα) could be a factor that plays a role in PGC-1α
binding to DNA. ERRα is encoded by the ESRRA gene and is an orphan nuclear receptor,
which has two domains. One of them allows the interaction with DNA, and the second one
with a ligand. The ERRα structure is similar to that of the estrogen receptor alpha
(ERα), but this receptor does not bind to natural estrogens. ERRα interacts with a
canonical sequence of the estrogen response elements (ERRE). ERRα and ERα could compete
with each other to bind to similar DNA elements. Together, ERRα binds to DNA, in complex
with PGC-1α, to regulate the activity of genes such as FNDC5 .
CA15-3, a high molecular weight glycoprotein (300-450 kDa), is produced by the epithelial
ducts and acinic breast cells and is then secreted in milk normally. It has been widely
used for the prediction of bone metastases in patients with breast cancer .
Criteria for eligibility:
Study pop:
A Case control study will be conducted on 100 patients with histologically confirmed
breast cancer, and a control group of 50 healthy volunteers with no clinical evidence of
any neoplastic disorder.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- histologically confirmed breast cancer
Exclusion Criteria:
- • History of other tumors.
Gender:
All
Minimum age:
20 Years
Maximum age:
70 Years
Locations:
Facility:
Name:
Sohag university Hospital
Address:
City:
Sohag
Zip:
Sohag
Country:
Egypt
Contact:
Last name:
Magdy M Amin, professor
Start date:
June 1, 2023
Completion date:
June 1, 2024
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05876728
